NASDAQ:ARTLW Artelo Biosciences (ARTLW) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free ARTLW Stock Alerts $0.01 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0118▼$0.011850-Day Range$0.01▼$0.0452-Week Range$0.01▼$0.21VolumeN/AAverage Volume6,579 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Artelo Biosciences alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Artelo Biosciences Stock (NASDAQ:ARTLW)Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Read More ARTLW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTLW Stock News HeadlinesMarch 28, 2024 | uk.investing.comArtelo Biosciences Inc (ARTL)March 27, 2024 | markets.businessinsider.comBuy Rating on Artelo Biosciences: Strong Pipeline and Market PotentialApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 25, 2024 | investorplace.comARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023March 25, 2024 | benzinga.comRecap: Artelo Biosciences Q4 EarningsMarch 12, 2024 | finance.yahoo.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeFebruary 15, 2024 | finance.yahoo.comArtelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thJanuary 23, 2024 | finance.yahoo.comArtelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral NeuropathyApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.November 30, 2023 | finance.yahoo.comArtelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNovember 9, 2023 | finance.yahoo.comArtelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain CancersOctober 4, 2023 | finance.yahoo.comPrincipal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and CachexiaSeptember 13, 2023 | finance.yahoo.comArtelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20thSeptember 7, 2023 | finance.yahoo.comArtelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12September 6, 2023 | finance.yahoo.comArtelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12thAugust 10, 2023 | finance.yahoo.comArtelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 19, 2023 | finance.yahoo.comArtelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023July 10, 2023 | finance.yahoo.comArtelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11June 28, 2023 | finance.yahoo.comArtelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society SymposiumJune 26, 2023 | msn.comArtelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In CanadaJune 26, 2023 | finance.yahoo.comArtelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society SymposiumJune 7, 2023 | finance.yahoo.comArtelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society SymposiumMarch 31, 2023 | finance.yahoo.comArtelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business UpdateFebruary 2, 2023 | finance.yahoo.comArtelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossJanuary 26, 2023 | finance.yahoo.comArtelo Biosciences to Present at Sequire Biotechnology Conference on February 2ndSeptember 1, 2022 | uk.finance.yahoo.comArtelo Biosciences, Inc. (ARTLW)August 16, 2022 | marketwatch.comArtelo Biosciences Shares Up on Promising Antianxiety ResearchSee More Headlines Receive ARTLW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ARTLW CUSIPN/A CIK1621221 Webwww.artelobio.com Phone858-925-7049FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Gregory D. Gorgas M.B.A. (Age 61)President, CEO, CFO, Treasurer, Secretary & Director Comp: $742.45kDr. Andrew Yates Ph.D.Senior VP & Chief Scientific OfficerDr. Steven D. Reich (Age 78)Chief Medical Officer Mr. Jason H. Baybutt (Age 52)Senior Vice President of Finance Key Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWBioCardiaNASDAQ:BCDAWView All Competitors ARTLW Stock Analysis - Frequently Asked Questions How have ARTLW shares performed in 2024? Artelo Biosciences' stock was trading at $0.0399 on January 1st, 2024. Since then, ARTLW shares have decreased by 70.4% and is now trading at $0.0118. View the best growth stocks for 2024 here. How do I buy shares of Artelo Biosciences? Shares of ARTLW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARTLW) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
